Sertraline Transfer into Breast Milk
Sertraline is transferred into breast milk at very low levels, with infant exposure representing less than 2% of the weight-adjusted maternal dose, making it one of the safest antidepressants for breastfeeding mothers.
Quantitative Data on Milk Transfer
Milk-to-Plasma Ratio
The milk-to-plasma (M/P) ratio for sertraline shows considerable variability across studies:
- Mean M/P ratio: 1.93 for sertraline and 1.64 for its metabolite N-desmethylsertraline 1
- Range reported from 0.42 to 4.81 in individual samples 2
- Overall ratio of 1.76 ± 1.72 in another cohort 3
Key clinical point: While the M/P ratio exceeds 1 (indicating higher concentrations in milk than plasma), this does not translate to clinically significant infant exposure due to the small volume of milk consumed relative to maternal dose 4.
Actual Infant Exposure
The most clinically relevant measure is the Relative Infant Dose (RID), which quantifies what percentage of the maternal dose (adjusted for weight) reaches the infant:
- RID: 0.54% (0.49%) for sertraline when calculated from actual milk production 5
- Combined sertraline plus metabolite exposure: 0.2% + 0.3% = 0.5% of weight-adjusted maternal dose 5
- When using estimated milk production (0.15 L/kg/day), RID increases to 0.90% for sertraline and 1.32% for metabolite, totaling approximately 2.2% 5
- Another study reported mean daily infant dose of 6.9 μg/kg after 50 mg maternal dose, representing 0.95% of weight-adjusted maternal dose 1
This is well below the 10% safety threshold considered acceptable for medications during lactation 6.
Factors Affecting Transfer
Timing and Milk Composition
Sertraline concentrations in breast milk are not uniform:
- Highest concentrations occur in hindmilk 7-10 hours after maternal dose 2, 7
- Significant gradient exists from foremilk to hindmilk 2, 7
- Milk fat content significantly impacts transfer: doubling milk fat content increases M/P ratio by 95% 1
Maternal Factors
- CYP2C19 poor metabolizers have 42% reduced sertraline clearance, potentially affecting milk concentrations 1
- Maternal dose correlates with milk concentrations, but relationship is not perfectly linear 3
Infant Plasma Concentrations
Most reassuring finding: Sertraline is rarely detectable in infant plasma despite presence in milk:
- Sertraline undetectable in 4 out of 4 infants tested in one study 5
- Detectable in only 3 of 11 infants (27%) in another study 7
- Detectable in 4 of 15 infants (27%) for sertraline, but 0 of 15 had detectable levels in the most recent study 4
- N-desmethylsertraline metabolite more commonly detected (50-55% of infants) but at very low levels 2, 7
When detected, infant plasma levels are below therapeutic range and below detection limits of most commercial laboratories 7.
Safety Profile
No adverse effects have been reported in breastfed infants across multiple studies:
- No adverse events in any of 8 infants 5
- No adverse effects in 11 infants 7
- All infants achieved normal developmental milestones 5
- No reported adverse effects in 15 infants 4
Clinical Recommendations
Sertraline is considered a preferred antidepressant during breastfeeding 4. The FDA label notes that "it is not known whether, and if so in what amount, sertraline or its metabolites are excreted in human milk" and recommends caution 8, but this conservative language predates the robust clinical evidence demonstrating safety.
Practical Considerations
- No need to interrupt breastfeeding when taking sertraline
- No need to "pump and dump" - while discarding milk 9 hours post-dose could theoretically reduce infant exposure by 17%, this is unnecessary given already minimal exposure 2
- Monitoring infant for drowsiness or poor feeding is reasonable but adverse effects are extremely unlikely given the data
Comparison to Other SSRIs
Among the three most studied SSRIs in lactation, sertraline and paroxetine are preferred over citalopram, as they result in mostly undetectable infant plasma levels 4.